Navigation Links
Shortages of Potassium Iodide as Radiation Panic Drives Demand
Date:3/28/2011

DENVER, March 28, 2011 /PRNewswire/ -- The Japanese nuclear crisis has caused a surge in the demand of potassium iodide, causing shortages not only in Japan, but as far away as California, western Canada, and even southeastern Russia. Although potassium iodide does not provide generalized radiation protection because it only shields the thyroid, manufacturers and pharmacies are being bombarded with orders as the radiation hysteria mounts.

A new and superior product, known as the BioShield Radiation Pill, could restore calm to worried residents in affected areas. Scientists at Premier Micronutrient Corporation have developed this pill as the first ever that is proven to protect DNA from damage caused by radiation. The product was originally developed at the request of the Marine Corps after 9/11 to protect military personnel from the adverse effects of radiation they might encounter while fighting in the Middle East. Research conducted with the Department of Defense, NASA, and prominent universities has demonstrated effectiveness in addressing radiation-induced oxidative stress.

Dr. James Ehrlich was on the team that developed this groundbreaking pill. Invite this engaging and knowledgeable guest to answer:

  • Should all residents near nuclear plants have the BioShield pill in case of a radiation emergency?
  • Is this pill safe for young children?
  • How does the BioShield pill work differently from potassium iodide?
  • How long after exposure can this pill provide protective benefits?
  • Is this pill available without a prescription?

CREDENTIALS: Dr. James Ehrlich is a Clinical Associate Professor at the University of Colorado and an Adjunct Assistant Professor in the department of medicine at the George Washington University Medical Center. He is the medical director of Early Detection Technologies, LLC, which advises on best practices involving biomarkers, imaging technologies, and radiation protection. Involved in atherosclerosis research at two medical schools, Dr. Ehrlich is a founding member of the Society of Atherosclerosis Imaging, a co-founder of the Society of Cardiovascular CT, and he created the Society for Responsible Preventive Imaging. He is head of the medical advisory board of U.S. Preventive Medicine and is on the board of Premier Micronutrient Corporation with a particular focus on biologic radiation protection. Dr. Ehrlich is a co-author of a multimedia CD called The Physician's Guide to Coronary Imaging. He has appeared on over 200 TV and radio programs nationwide.

CONTACT: James Ehrlich, M.D., (303) 808-6470 (CO); earlydetectdoc@gmail.com; http://www.bioshieldpill.com and http://www.premiermicronutrient.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Premier Micronutrient Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Study Shows Nu-Tek's Modified Potassium Chloride Improves Yields in Meat Processing
2. 50,000 Potassium Iodide Pills Donated to Japan
3. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
4. New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric
5. Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
6. Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology
7. Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. New near-field radiation therapy promises relief for overheating laptops
10. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
11. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
Breaking Biology Technology:
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):